Skip to main content
OpenTrials
Completed

NCT Number: NCT06837987

Modified Transplantation Regimen and aGVHD Prophylaxis for Severe Aplastic Anemia in the Setting of Allogeneic HSCT.

The investigators retrospectively evaluted the safety and efficacy of the modified transplantation conditioning and aGVHD prophylaxis in severe aplastic anemia in 4 transplantation centers.

Completed

Looking for future studies?

Notify Me

Key information

Age range

3 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Department of Hematology,920th Hospital of Joint Logistics Support Force

Kunming, Yunnan, 650000, China

About this study

Aplastic anemia (AA) is a group of myelo-hemopoietic failure syndromes caused by a variety of etiologies. If not intervened, the average expected survival time is less than half a year.Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is one of the possible cures for this disease. The success rate of treatment for this disease can be further improved under the previous regimen system. The survival rate reported in the literature is 60%-90%. From Jun. 2020 to Dec. 2023, 72 patients in 4 transplantation center received this modified transplantation system, The investigators designed this clinical trial to retrospectively evaluted the safety and efficacy of the modified transplantation conditioning and aGVHD prophylaxis in severe aplastic anemia in the 4 clinical center.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who were diagnosed with severe aplastic anemia by NCCN guidelines, and has received HSCT with this transplantation preconditioning and aGVHD prophylaxis regimen;
  • Age 3-65 years old;
  • Weight 10Kg-100Kg;
  • Eastern Cooperative Oncology Group (ECOG) score ≤3;
  • No major organ injury (ECG ejection fraction >45%; bilirubin < 2 times the upper limit of normal value; AST and ALT < 3 times the upper limit of normal value; serum creatinine < 2 times the upper limit of normal value);
  • No severe infection;
  • Subjects voluntarily participated in this clinical trial and signed the informed consent.

Exclusion criteria

  • Patients with other hematologic diseases who are not eligible for transplantation or who do not wish to receive transplantation;
  • Patients with an expected survival of less than 1 month;
  • Patients with previous autologous or allogeneic hematopoietic stem cell transplantation;
  • pregnant patients;
  • Patients with severe mental or neurological disorders that would affect the ability to provide informed consent and/or to report or observe adverse events;
  • Other conditions that the investigator determines to be inappropriate for enrollment.

Treatment and study plan

Modified transplantation system

Other

Modified transplantation conditioning include: Fludarabine 30mg/m2*6 day, Melphalan 100mg/m2*1 day, cyclophosphamide 50mg/kg*2 day.

Primary outcomes

  1. Primary graft falure rate

    Time frame: From the day of HSCs transfusion to +100 day after HSCT.

    no apperance or complete loss of donor-derived neutrophils by +28 days

  2. aGVHD incidence

    Time frame: From the day of HSCT transfusion to 100 days after HSCT

    proportion of patients who developed aGVHD within 100 days after HSCT

Secondary outcomes

  1. Poor graft function rate

    Time frame: From the day of HSCs transfusion to 24 months after HSCT

    the presence of at least two cytopenic counts beyond +28 days with a transfusion requirement associated with hypoplastic-aplastic bone marrow

  2. cGVHD incidence

    Time frame: From +100 days after HSCT to the follow-up date

    the proportion of patients who developed chronic GVHD within the observation duration

  3. adverse events

    Time frame: From the first day of preconditioning to +100 days after hematopoietic stem cell Transfusion

    the incidence of adverse events during the transplantation preconditioning periods.

  4. 2-year Overall survival rate

    Time frame: 24 months

    proportioin of patients who still be alive within 24 months after HSCT

  5. Disease-free survival

    Time frame: 24 months

    proportion of patients still be alive without GVHD or other diseases.

Sponsors and collaborators

Lead sponsor

Hematology department of the 920th hospital

Other

Registry information

Official study title

An Observation of the Safety and Efficacy of a Modified Transplantation Conditioning and aGVHD Prophylaxis for Severe Aplastic Anemia--a Retrospective, Double-center, Single-arm Clinical Study.

Acronym: aGVHD

Important dates

Study start
2020
Primary completion
2023
Study completion
2025
First posted
Feb 20, 2025
Registry last updated
Sep 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.